同: Proventil, Ventolin, Vomax
関: Albuterol

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/08/11 03:22:10」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児における高カリウム血症のマネージメント management of hyperkalemia in children
2. Asthma in children younger than 12 years: Rescue treatment for acute symptoms
3. 食品添加物に対するアレルギー反応および喘息反応を評価するための検査法およびチャレンジテスト testing and challenge procedures to evaluate allergic and asthmatic reactions to food additives
4. Acute asthma exacerbations in children: Emergency department management
5. 慢性閉塞性肺疾患（COPD）における抗コリン療法の役割 role of anticholinergic therapy in copd

English Journal

Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.

Koeberl DD, Austin S, Case LE, Smith EC, Buckley AF, Young SP, Bali D, Kishnani PS.Author information *Division of Medical Genetics, Department of Pediatrics, †Division of Physical Therapy, Department of Community and Family Medicine, ‡Division of Pediatric Genetics, Department of Pediatrics, and §Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA.AbstractEffective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased CI-MPR-mediated uptake of recombinant human acid-α-glucosidase during ERT in mice with Pompe disease following addition of albuterol therapy. Currently we have completed a pilot study of albuterol in patients with late-onset Pompe disease already on ERT for >2 yr, who were not improving further. The 6-min walk test (6MWT) distance increased in all 7 subjects at wk 6 (30±13 m; P=0.002), wk 12 (34±14 m; P=0.004), and wk 24 (42±37 m; P=0.02), in comparison with baseline. Grip strength was improved significantly for both hands at wk 12. Furthermore, individual subjects reported benefits; e.g., a female patient could stand up from sitting on the floor much more easily (time for supine to standing position decreased from 30 to 11 s), and a male patient could readily swing his legs out of his van seat (hip abduction increased from 1 to 2+ on manual muscle testing). Finally, analysis of the quadriceps biopsies suggested increased CI-MPR at wk 12 (P=0.08), compared with baseline. With the exception of 1 patient who succumbed to respiratory complications of Pompe disease in the first week, only mild adverse events have been reported, including tremor, transient difficulty falling asleep, and mild urinary retention (requiring early morning voiding). Therefore, this pilot study revealed initial safety and efficacy in an open label study of adjunctive albuterol therapy in patients with late-onset Pompe disease who had been stable on ERT with no improvements noted over the previous several years.-Koeberl, D. D., Austin, S., Case, L. E., Smith, E. C., Buckley, A. F., Young, S. P., Bali, D., Kishnani, P. S. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.FASEB J.2014 Jan 17. [Epub ahead of print]
Effective dosages for enzyme replacement therapy (ERT) in Pompe disease are much higher than for other lysosomal storage disorders, which has been attributed to low cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle. We have previously demonstrated the benefit of increased C
PMID 24443373

Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation.

Blonder JP, Mutka SC, Sun X, Qiu J, Green LH, Mehra NK, Boyanapalli R, Suniga M, Look K, Delany C, Richards JP, Looker D, Scoggin C, Rosenthal GJ.Author information N30 Pharmaceuticals, Inc, 3122 Sterling Circle, Suite 200, Boulder, CO 80301, USA. joan.blonder@n30pharma.com.AbstractBACKGROUND: S-nitrosoglutathione (GSNO) serves as a reservoir for nitric oxide (NO) and thus is a key homeostatic regulator of airway smooth muscle tone and inflammation. Decreased levels of GSNO in the lungs of asthmatics have been attributed to increased GSNO catabolism via GSNO reductase (GSNOR) leading to loss of GSNO- and NO- mediated bronchodilatory and anti-inflammatory actions. GSNOR inhibition with the novel small molecule, N6022, was explored as a therapeutic approach in an experimental model of asthma.
BMC pulmonary medicine.BMC Pulm Med.2014 Jan 10;14(1):3. doi: 10.1186/1471-2466-14-3.
BACKGROUND: S-nitrosoglutathione (GSNO) serves as a reservoir for nitric oxide (NO) and thus is a key homeostatic regulator of airway smooth muscle tone and inflammation. Decreased levels of GSNO in the lungs of asthmatics have been attributed to increased GSNO catabolism via GSNO reductase (GSNOR)
PMID 24405692

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.AbstractABSTRACT BACKGROUND: Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease (COPD).
Chest.Chest.2014 Jan 2. doi: 10.1378/chest.13-1579. [Epub ahead of print]
ABSTRACT BACKGROUND: Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease (COPD).OBJECTIVES: To compare the efficacy and safety of once-daily umeclidinium/vilanterol (UMEC/VI) 125/25 mcg with placebo
PMID 24385182

Related Pictures

Ventolin - drug review: dosage, side Ventolin is the most well-known reliever Di Bordo 1984: -Ventolin La Soluzione Ventolin | Salbutamol | Tratamiento del Buy Ventolin - Evohaler or Accuhaler Ventolin* - albuterol (scroll down to see